Company / R&D Expense
Medtronic R&D Expense History
FY2017-FY2026 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$2.7B
FY2026
5-year range
$2.3B / $2.7B
FY2022-FY2026
Trend
+1.4%
vs FY2025
Sector context
#2 of 110
Health Care
What the data says
Among 110 Health Care companies, Medtronic is in the top 2% for r&d expense. R&D Expense has fluctuated over the past 10 years, ranging from $2.3B in FY2017 to $2.7B in FY2026.
Based on SEC 10-K filings.
$2.7B in FY2026 with a 5-year CAGR of +3.3%. Ranks 2nd among 110 companies in Health Care.
Remained stable around $2.7B over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +3.1%
- 5-Year CAGR
- +3.3%
- 10-Year CAGR
- -
Sector benchmark
Top 2% in Health CareTop 2% of 110This company $2.7B Sector average $298.2M
▼
+817.2% above sector average
Key checks
Key Insights
- 5-year CAGR of +3.3%, indicating consistent growth.
- In FY2026, r&d expense increased 1.4% year-over-year.
- Ranks #2 out of 110 companies in the Health Care sector.
- Lowest r&d expense in the period was in FY2017.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2026 | $2.7B | +1.4% |
| FY2025 | $2.7B | -1.3% |
| FY2024 | $2.7B | +9.6% |
| FY2023 | $2.5B | +6.9% |
| FY2022 | $2.3B | +0.0% |
| FY2021 | $2.3B | -6.5% |
| FY2020 | $2.5B | +6.9% |
| FY2019 | $2.3B | +0.0% |
| FY2018 | $2.3B | +3.3% |
| FY2017 | $2.3B | +2.9% |
As of FY2026 · SEC 10-K · Updated Jun 30, 2026